SPI Infoamtion

1 Table of contents
1.1 List of Tables
1.2 List of Figures

2 Renal Cancer: Market Characterization
2.1 Renal Cancer Market Size
2.2 Renal Cancer Market Forecast and CAGR
2.3 Drivers and Barriers for Renal Cancer Market
2.3.1 Drivers for Renal Cancer Market
2.3.2 Barriers for Renal Cancer Market
2.4 Opportunity and Unmet Need
2.5 Key Takeaway

3 Renal Cancer Market: Competitive Assessment
3.1 Overview
3.2 Strategic Competitor Assessment
3.3 Product Profile for the Major Marketed Products in Renal Cancer Market
3.3.1 Avastin (bevacizumab)
3.3.2 Sutent (sunitinib malate)
3.3.3 Votrient (pazopanib)
3.3.4 Afinitor (everolimus)
3.3.5 Nexavar (sorafenib)
3.3.6 Torisel (temsirolimus)
3.4 Major Marketed Products Comparison in Renal Cancer Market
3.5 Key Takeaway

4 Renal Cancer Market: Pipeline Assessment
4.1 Overview
4.2 Strategic Pipeline Assessment
4.2.1 Technology Trends Analytic Framework
4.3 Renal Cancer Therapeutics – Promising Drugs Under Clinical Development
4.4 Molecule Profile for Promising Drugs under Clinical Development
4.4.1 Oncophage (vitespen)
4.4.2 Axitinib
4.4.3 TroVax
4.4.4 ANYARA
4.4.5 RENCAREX
4.5 Renal Cancer Therapeutics Market – Clinical Pipeline by Therapeutic Class
4.6 Renal Cancer Pipeline – Pipeline by Clinical Phases of Development
4.6.1 Renal Cancer Therapeutics – Regulatory Filed Clinical Pipeline
4.6.2 Renal Cancer Therapeutics – Phase III Clinical Pipeline
4.6.3 Renal Cancer Therapeutics – Phase II Clinical Pipeline
4.6.4 Renal Cancer Therapeutics – Phase I Clinical Pipeline
4.6.5 Renal Cancer Therapeutics – Preclinical Pipeline
4.6.6 Renal Cancer Therapeutics – Drug Discovery Pipeline
4.7 Key Takeaway

5 Global Renal Cancer: Implications for Future Market Competition

6 Global Renal Cancer Market: Future Players in the Renal Cancer Market
6.1 Introduction
6.2 F. Hoffmann-La Roche Ltd/Genentech, Inc.
6.2.1 Company Overview
6.2.2 Business Description
6.3 Pfizer Inc.
6.3.1 Company Overview
6.3.2 Business Description
6.4 Novartis AG
6.4.1 Company Overview
6.4.2 Business Description
6.5 Amgen Inc.
6.5.1 Company Overview
6.5.2 Business Description
6.6 WILEX AG
6.6.1 Company Overview
6.6.2 Business Description

7 Global Renal Cancer Market: Appendix
7.1 Definitions
7.2 Acronyms
7.3 Research Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Forecasting
7.3.4 Primary Research
7.3.5 Expert Panels
7.4 Contact Us
7.5 Disclaimer
7.6 Sources

List of Figures
Figure 1: Global Renal Cancer Therapeutics Market Forecast, 2001–2016
Figure 2: Renal Cancer Therapeutics Market – Opportunity and Unmet Need, 2009
Figure 3: Renal Cancer Therapeutics Market – Strategic Competitor Assessment, 2009
Figure 4: Technology Trends Analytic Framework of the Renal Cancer Pipeline, 2009
Figure 5: Technology Trends Analytic Framework of the Renal Cancer Pipeline – Description, 2009
Figure 6: Renal Cancer Therapeutics Market – Clinical Pipeline by Mechanism Of Action, 2009
Figure 7: Renal Cancer Pipeline by Phase of Clinical Development, 2009
Figure 8: Renal Cancer Therapeutics Market – Strategic Competitor Assessment, 2009
Figure 9: Renal Cancer Therapeutics Market – Clinical Pipeline by Company, 2009
Figure 10: GlobalData Methodology
Figure 11: GlobalData Market Forecasting Model

List of Tables
Table 1: Global Renal Cancer Therapeutics Market, Revenue Forecasts ($ m), 2001–2009
Table 2: Global Renal Cancer Therapeutics Market, Revenue Forecasts ($ m), 2010–2016
Table 3: Major marketed products comparison in Renal Cancer Market, 2009
Table 4: Renal Cancer Therapeutics – Most Promising Drugs Under Clinical Development, 2009
Table 5: Renal Cancer Therapeutics – Regulatory Filed Clinical Pipeline, 2009
Table 6: Renal Cancer Therapeutics – Phase III Clinical Pipeline, 2009
Table 7: Renal Cancer Therapeutics – Phase II Clinical Pipeline, 2009
Table 8: Renal Cancer Therapeutics – Phase I Clinical Pipeline, 2009
Table 9: Renal Cancer Therapeutics – Preclinical Pipeline, 2009
Table 10: Renal Cancer Therapeutics – Drug Discovery Pipeline, 2009
Table 11: F. Hoffmann-La Roche Ltd/Genentech, Inc. – Oncology Pipeline Products, 2009
Table 12: F. Hoffmann-La Roche Ltd/Genentech, Inc. – Renal Cancer Pipeline Products, 2009
Table 13: Pfizer Inc – Oncology Pipeline Products, 2009
Table 14: Pfizer Inc – Renal Cancer Pipeline Products, 2009
Table 15: Novartis AG – Oncology Pipeline Products, 2009
Table 16: Novartis AG – Renal Cancer Pipeline Products, 2009
Table 17: Amgen Inc. – Oncology Pipeline Products, 2009
Table 18: Amgen Inc. – Renal Cancer Pipeline Products, 2009
Table 19: WILEX AG – Oncology Pipeline Products, 2009
Table 20: WILEX AG – Renal Cancer Pipeline Products, 2009